Klin Onkol 2008; 21(Suppl 1): 204-206.
From 2004 to 2006 we have used cIg-FISH method to analyze immunofl uorescence-labeled plasma cells from 208 patients with multiple myeloma (MM) enrolled in the CMG 2002 clinical trial. The aim of our study was to evaluate the frequency and prognostic impact of selected chromosomal aberrations. Chromosome 13 aberrations were found in 52,9% of patients, IgH gene translocations in 58,6% of patients, p53 gene deletions in 21,6% of patients, and 1q21 gains in 37,7% patients. Statistical analysis has shown that IgH translocations, 1q21 gain, and simultaneous presence of more than two different genetic aberrations were associated with aggressive course of the disease and poor prognosis. We have not confi rmed the putative negative prognostic impact of chromosome 13 aberrations
and the favorable prognosis associated with t(11;14)(q13;q32). There was a high degree of heterogeneity of genetic abnormalities in plasma cells and a high prevalence of multiple aberrations. Complex analysis of all detected chromosomal abnormalities is necessary for the evaluation of their impact on prognosis.
